MedTrace Logo

A Study of Patients Who Develop HIV Infection After Enrolling in HIV Vaccine Trials or HIV Vaccine Preparedness Trials

NCT00029913 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 54

Last updated 2010-09-02

No results posted yet for this study

Summary

Despite risk reduction counseling, some individuals in HIV vaccine trials or vaccine preparedness studies may engage in risk behavior that results in HIV infection. The purpose of the HVTN 403 study is to find out more about how persons respond to HIV infection if they have received an experimental HIV-1 vaccine before they became HIV infected.

Some people in HVTN 403 received an experimental HIV vaccine as a participant in a clinical trial before getting infected with HIV. Other people in this study were in a vaccine preparedness study when they got infected with HIV. None of these individuals became infected with HIV as result of their participation in an HIV vaccine or vaccine preparedness study. HVTN 403 will compare immune responses between those who previously received an experimental HIV vaccine and those who did not. Information learned from this study may be important in guiding future developments of new HIV vaccines and other treatments for HIV and AIDS.

Conditions

  • HIV Infections

Interventions

OTHER

Observation

Observation of participants who received HIV preventive vaccine and became infected.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • HIV Vaccine Trials Network

    lead NETWORK

Principal Investigators

  • Connie Celum, MD · University of Washington

  • Scott Hammer, MD · Columbia University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-04-30
Primary Completion
2009-07-31
Completion
2009-07-31

Countries

  • United States
  • Brazil
  • Peru
  • South Africa

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00029913 on ClinicalTrials.gov